Using regulatory CD8 T cells to calm autoimmune attacks in MS
Official title: Immunotherapeutic Regulatory CD8 T cells in Autoimmune Demyelinating Disease
Funded at Iowa City VA Medical Center · NIH-11138542 · Data updated 2026-11-12
This work explores whether a special type of immune cell (regulatory CD8 T cells) can be used to reduce the immune attack that damages nerves in people with multiple sclerosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iowa City VA Medical Center NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | July 1, 2017 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| NIH project number | 5I01BX003677-09 |
| Project ID | NIH-11138542 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with a diagnosis of multiple sclerosis—especially those with active or relapsing disease—would be the most likely candidates for future therapies based on this work.
✕Less likely to help
Patients with non‑autoimmune neurological conditions or those with long‑standing progressive MS without active inflammation may be less likely to benefit from immune‑based approaches.
What this research studies
Researchers are studying a type of CD8 immune cell that appears to suppress the damaging immune response in multiple sclerosis. They use an established animal model of MS to learn how these cells work, including the signals they use, how they travel to the brain and spinal cord, and how they stop inflammation. The team aims to identify a strong, boostable subset of these regulatory CD8 cells and test a vaccination approach to enhance their protective function. Results could point the way toward therapies that harness a person’s own immune cells to limit relapses and nerve damage.
Why it matters
Potential benefit: If successful, this approach could lead to new immunotherapies that reduce central nervous system inflammation and slow or prevent MS relapses and progression.
How similar studies have gone: Most past MS research targeted CD4 T cells, so using regulatory CD8 T cells is a relatively novel approach, though some animal and early human data suggest CD8 cells can suppress autoimmune damage.
Where this research is happening
-
Iowa City VA Medical Center
Iowa City, United States Active
Researchers
- Principal investigator: Karandikar, Nitin J — Iowa City VA Medical Center
- Study coordinator: Karandikar, Nitin J
Related research
Other NIH-funded projects on the same topics.
-
Biomarkers that predict how Parkinson’s will progress
This NIH grant aims to find markers, like brain imaging and blood tests, that could tell doctors early on which people with Parkinson’s are likely to see faster or slower disease progression.
-
Immune system and inflammation in blast-related brain injury progression
This project looks at how the body's immune response after blast-related brain injury may drive ongoing brain and eye damage, with potential therapies that are already approved for other uses.
-
New, practical metrics to improve how hospitals prescribe antibiotics
Aims to develop and test new metrics that better measure how well hospitals use antibiotics, with the goal of improving patient safety and reducing resistance.
-
Improving antimicrobial use at discharge by building on hospital stewardship
This grant explores how to reduce unnecessary antibiotic prescriptions after hospital discharge to help prevent infections and side effects.
-
Perioperative pain self-management to prevent long-term pain and opioid use
This project tests whether a short cognitive-behavioral perioperative pain self-management program helps surgical patients avoid chronic post-surgical pain and prolonged opioid use.
-
Center for Preventing and Treating Visual Loss in Veterans
A center-backed effort to detect early signs of eye and brain disorders that can cause blindness, using AI and advanced eye imaging to guide new treatments for Veterans and the general public.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.